Analysts' ratings for BioNTech (NASDAQ:BNTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, and a low estimate of $96.00. Marking an increase of 19.2%, the current average surpasses the previous average price target of $110.94.

Exploring Analyst Ratings: An In-Depth Overview

The standing of BioNTech among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of BioNTech's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on BioNTech analyst ratings.

Delving into BioNTech's Background

A Deep Dive into BioNTech's Financials

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Revenue Growth: Over the 3 months period, BioNTech showcased positive performance, achieving a revenue growth rate of 39.04% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: BioNTech's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 15.91%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): BioNTech's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.04% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): BioNTech's ROA excels beyond industry benchmarks, reaching 0.89%. This signifies efficient management of assets and strong financial health.

Debt Management: With a below-average debt-to-equity ratio of 0.01, BioNTech adopts a prudent financial strategy, indicating a balanced approach to debt management.

How Are Analyst Ratings Determined?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.